278 related articles for article (PubMed ID: 17962215)
1. In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action.
Laue H; Weiss L; Bernardi A; Hawser S; Lociuro S; Islam K
J Antimicrob Chemother; 2007 Dec; 60(6):1391-4. PubMed ID: 17962215
[TBL] [Abstract][Full Text] [Related]
2. Iclaprim, a novel diaminopyrimidine for the treatment of resistant gram-positive infections.
Sincak CA; Schmidt JM
Ann Pharmacother; 2009 Jun; 43(6):1107-14. PubMed ID: 19435963
[TBL] [Abstract][Full Text] [Related]
3. Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity.
Oefner C; Bandera M; Haldimann A; Laue H; Schulz H; Mukhija S; Parisi S; Weiss L; Lociuro S; Dale GE
J Antimicrob Chemother; 2009 Apr; 63(4):687-98. PubMed ID: 19211577
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of tigecycline combined with other antimicrobials against multiresistant gram-positive and gram-negative pathogens.
Vouillamoz J; Moreillon P; Giddey M; Entenza JM
J Antimicrob Chemother; 2008 Feb; 61(2):371-4. PubMed ID: 18033780
[TBL] [Abstract][Full Text] [Related]
5. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis.
Petersen PJ; Labthavikul P; Jones CH; Bradford PA
J Antimicrob Chemother; 2006 Mar; 57(3):573-6. PubMed ID: 16431863
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory properties and X-ray crystallographic study of the binding of AR-101, AR-102 and iclaprim in ternary complexes with NADPH and dihydrofolate reductase from Staphylococcus aureus.
Oefner C; Parisi S; Schulz H; Lociuro S; Dale GE
Acta Crystallogr D Biol Crystallogr; 2009 Aug; 65(Pt 8):751-7. PubMed ID: 19622858
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of dihydrofolate reductase inhibitors and other antibiotics against Gram-positive pathogens collected globally between 2004 and 2016.
Noviello S; Hawser S; Sader H; Huang DB
J Glob Antimicrob Resist; 2019 Mar; 16():236-238. PubMed ID: 30612987
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of iclaprim and comparison agents tested against Neisseria gonorrhoeae including medium growth supplement effects.
Jones RN; Biedenbach DJ; Sader HS
Diagn Microbiol Infect Dis; 2009 Mar; 63(3):339-41. PubMed ID: 19216944
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the in vitro activity of ertapenem and nine other comparator agents against 337 anaerobic bacteria.
Behra-Miellet J; Dubreuil L; Calvet L
Int J Antimicrob Agents; 2006 Jul; 28(1):25-35. PubMed ID: 16757152
[TBL] [Abstract][Full Text] [Related]
10. Synergic activity of beta-lactamines and aminoglycosides vs. bacterial strains treated with sub-MIC concentrations.
Gismondo MR; Romeo MA; Pappalardo C; Puglisi G; Leonardi R
Chemioterapia; 1984 Jun; 3(3):175-7. PubMed ID: 6529773
[TBL] [Abstract][Full Text] [Related]
11. [Mechanisms of antimicrobial resistance].
Hori S; Hiramatsu K
Nihon Rinsho; 1994 Feb; 52(2):327-31. PubMed ID: 8126881
[TBL] [Abstract][Full Text] [Related]
12. Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and Europe.
Huang DB; File TM; Dryden M; Corey GR; Torres A; Wilcox MH
Diagn Microbiol Infect Dis; 2018 Apr; 90(4):329-334. PubMed ID: 29306582
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interaction of Helichrysum pedunculatum leaf extracts with antibiotics against wound infection associated bacteria.
Aiyegoro OA; Afolayan AJ; Okoh AI
Biol Res; 2009; 42(3):327-38. PubMed ID: 19915741
[TBL] [Abstract][Full Text] [Related]
14. In vitro antimicrobial activity of propolis and synergism between propolis and antimicrobial drugs.
Stepanović S; Antić N; Dakić I; Svabić-Vlahović M
Microbiol Res; 2003; 158(4):353-7. PubMed ID: 14717457
[TBL] [Abstract][Full Text] [Related]
15. Synergism and antagonism.
Eliopoulos GM
Infect Dis Clin North Am; 1989 Sep; 3(3):399-406. PubMed ID: 2671129
[TBL] [Abstract][Full Text] [Related]
16. Iclaprim: a differentiated option for the treatment of skin and skin structure infections.
Noviello S; Huang DB; Corey GR
Expert Rev Anti Infect Ther; 2018 Nov; 16(11):793-803. PubMed ID: 30317894
[TBL] [Abstract][Full Text] [Related]
17. In vitro antibacterial activity of aminosterols against multidrug-resistant bacteria from patients with cystic fibrosis.
Alhanout K; Brunel JM; Raoult D; Rolain JM
J Antimicrob Chemother; 2009 Oct; 64(4):810-4. PubMed ID: 19666647
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of some novel polysubstituted pyrimidine derivatives as potential antimicrobial and anticancer agents.
Rostom SA; Ashour HM; Abd El Razik HA
Arch Pharm (Weinheim); 2009 May; 342(5):299-310. PubMed ID: 19415663
[TBL] [Abstract][Full Text] [Related]
19. Iclaprim, a dihydrofolate reductase inhibitor antibiotic in Phase III of clinical development: a review of its pharmacology, microbiology and clinical efficacy and safety.
Huang DB; Dryden M
Future Microbiol; 2018 Jul; 13():957-969. PubMed ID: 29742926
[TBL] [Abstract][Full Text] [Related]
20. Worldwide surveillance of Iclaprim activity: In Vitro susceptibility of gram-positive pathogens collected from patients with skin and skin structure infections from 2013 to 2017.
Huang DB; Charrier C; Hawser S
Diagn Microbiol Infect Dis; 2020 May; 97(1):115013. PubMed ID: 32081524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
